Switzerland · Delayed Price · Currency is CHF Lonza Group AG Earnings Call Transcripts
Fiscal Year 2026
-
A major portfolio transformation is complete with the divestment of 60% of CHI, focusing the business as a pure-play CDMO. Proceeds of at least CHF 3 billion will fund organic growth, bolt-on M&A, and a CHF 500 million share buyback, with 2026 guidance unchanged.
-
A major portfolio transformation is completed with the divestment of 60% of CHI, enabling a pure-play CDMO focus. Proceeds of at least CHF 3 billion will fund organic growth, acquisitions, and a CHF 500 million share buyback, while the 2026 outlook remains robust.
-
A clear strategy and robust financial model underpin strong growth, with major investments in global capacity and technology. The Vacaville acquisition strengthens U.S. presence, while ongoing regionalization and high customer retention support long-term value creation.
Fiscal Year 2025
-
Delivered CHF 6.5 billion in sales (+21.7% constant currency), with core EBITDA margin up to 31.6% and free cash flow nearly doubling. Outlook for 2026 is 11%-12% sales growth and margin above 32%, supported by strong segment performance and disciplined capital allocation.
-
Strong Q3 performance and robust contracting support confirmation of 2025 outlook, with CDMO sales growth of 20–21% and margin of 30–31%. Vacaville and CHI businesses are progressing as planned, and growth projects remain on track despite FX and funding headwinds.
-
Delivered strong H1 2025 results with 19% CER sales growth and upgraded full-year CDMO guidance to 20%-21% sales growth and 30%-31% core EBITDA margin. Integrated Biologics and Advanced Synthesis drove performance, while CHI recovery and major CapEx projects progressed.
-
Strong Q1 2025 performance supports a confirmed outlook for nearly 20% sales growth and a core EBITDA margin near 30%. Segment momentum is robust, with high asset utilization and ongoing growth projects, while risk from tariffs and FX is mitigated by global footprint and hedging.
-
A new unified vision and strategy were outlined, focusing on becoming a pure-play CDMO and leveraging the Lonza Engine for growth. The company is exiting the CHI business, investing in global capacity, and targeting low-teens organic growth, with strong execution and positive market outlook.
Fiscal Year 2024
-
2024 results showed stable revenues at CHF 6.6 billion, with strong CDMO growth offsetting CHI declines. 2025 guidance anticipates CDMO revenue growth near 20% and margin expansion, supported by new capacity and the Vacaville acquisition.
-
A new unified strategy and organizational structure were unveiled, focusing on the 'Lonza Engine' to drive above-market growth, operational excellence, and value creation. Guidance was updated to a rolling, organic growth model, with low-teens sales growth and margins approaching 30%, while the CHI business will be divested.
-
Q3 performance is on track with full-year guidance, with strong momentum in Biologics, Small Molecules, and Cell and Gene divisions. CapEx will be slightly below guidance, and key growth projects are progressing, while Capsules and BioScience divisions are expected to recover in 2025.
-
H1 2024 saw 1.8% sales growth and a 29.2% core EBITDA margin, with strong CDMO performance offset by CHI headwinds. The Vacaville acquisition will double mammalian capacity, and full-year guidance for flat sales growth and high-20s EBITDA margin is reaffirmed.